I am holding shares of Aurobindo Pharma at an average cost of ₹740. Is there a possibility of a reversal? What is the outlook?
Ramanathan M
Aurobindo Pharma (₹480): The stock has been in a strong downtrend since June 2021. It made a low of ₹397.30 earlier this month and has risen sharply over the last couple of weeks. Though there is no significant sign of a reversal, a strong long-term trendline support is around ₹360. As such there is not much room left on the downside even if the stock reverses lower again.
Read also: Pharma Q3 FY23 numbers: Differentiation remains key
We expect the region around ₹360 would be the bottom for the current downtrend. A strong rally either from here itself or after testing ₹360 can take Aurobindo Pharma stock price up to ₹650-₹750 over the next one year. From a long-term perspective, that rally will have the potential to target ₹1,100 in the next couple of years and more than that.
If you are a long-term investor, buy more at current levels and also at ₹380 if a fall below ₹400 is seen. Keep a stop-loss at ₹310. Revise the stop-loss up to ₹585 as soon as the stock moves up to ₹730. Move the stop-loss further up to ₹740 when the stock touches ₹880. Exit the shares at ₹1,000.
Read more: Aurobindo Pharma gets USFDA nod for osteoarthritis drug
Please send your questions to techtrail@thehindu.co.in.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.